NCT07218510View on ClinicalTrials.gov

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 9, 2025

Primary Completion Date

August 11, 2028

Study Completion Date

August 11, 2028

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDURE

Computed Tomography

Undergo CT

OTHER

Electronic Health Record Review

Ancillary studies

BIOLOGICAL

Epcoritamab

Given SC

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Obinutuzumab

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (7)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

30265

City of Hope Atlanta Cancer Center, Newnan

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

53226

Medical College of Wisconsin, Milwaukee

90813

City of Hope at Long Beach Elm, Long Beach

91010

City of Hope Medical Center, Duarte

92618

City of Hope at Irvine Lennar, Irvine

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER